Mumbai, November 27 (Udaipur Kiran): Shares of Granules India were trading higher on the BSE after its overseas arm incorporated a wholly owned subsidiary in Canada. The stock was trading at Rs. 551.15, up by 5.15 points or 0.94 per cent from its previous close of Rs. 546.00.
The scrip opened at Rs. 544.65 and moved between a high of Rs. 555.75 and a low of Rs. 543.00 during the session. A total of 16,444 shares were traded on the counter so far.
The BSE Group ‘A’ stock, with a face value of Rs. 1, touched its 52-week high of Rs. 627.45 on December 3, 2024, and a 52-week low of Rs. 412.05 on April 7, 2025. Over the past one week, the stock moved between Rs. 530.00 and Rs. 555.75. The company’s current market capitalisation stands at Rs. 13,374.69 crore.
Promoters hold 38.82 per cent stake in the company, while institutional investors and non-institutional investors hold 32.01 per cent and 29.17 per cent respectively.
Granules India’s wholly owned foreign subsidiary, M/s Granules Pharmaceuticals, Inc., has incorporated a wholly owned subsidiary named ‘Granules Pharmaceuticals Canada, Inc.’ in Canada on November 26, 2025. Granules Pharmaceuticals, Inc. will hold 100 per cent of the equity capital in the newly incorporated company, which has not yet commenced business operations.
Granules India is engaged in the manufacture and supply of pharmaceutical products, including active pharmaceutical ingredients, formulation intermediates and finished dosage products.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.
Related
